免疫疗法
免疫系统
免疫学
肿瘤微环境
抗原
生物
逃避(道德)
T细胞
树突状细胞
免疫耐受
医学
胶质母细胞瘤
抑制器
癌症研究
细胞毒性T细胞
髓源性抑制细胞
免疫检查点
PD-L1
癌症免疫疗法
主要组织相容性复合体
作者
Cheng Cheng,Yuxing Wang,YiRu Wen,Yaqiang Bai,Yanni Xia,Yue Feng,Zeping Chen
出处
期刊:Biofactors
[Wiley]
日期:2026-07-01
卷期号:52 (4): e70132-e70132
摘要
Glioblastoma (GBM) is the most aggressive primary brain tumor, marked by poor prognosis and resistance to conventional therapies. A critical barrier to effective treatment lies in its highly immunosuppressive and heterogeneous tumor microenvironment (TME), which orchestrates immune evasion and therapeutic failure. Tumor-associated macrophages (TAMs), particularly those with an M2-like phenotype, sustain GBM proliferation, angiogenesis, and stem-like cell maintenance. Dysfunctional T lymphocytes-especially the accumulation of regulatory T cells-further attenuate anti-tumor immunity. Natural killer (NK) cells, dendritic cells, neutrophils, and myeloid-derived suppressor cells (MDSCs) also contribute to immune suppression through distinct yet interconnected mechanisms. Despite the success of immunotherapies in other malignancies, immune checkpoint inhibitors, CAR-T cells, and tumor vaccines have yielded limited efficacy in GBM, hindered by low neoantigen burden, antigenic heterogeneity, and poor immune infiltration. Overcoming these challenges requires a systems-level understanding of the immunoregulatory circuits within the GBM TME and the development of combination immunotherapies guided by predictive biomarkers. This review systematically delineates the roles of immune components in GBM immunopathology and outlines the emerging therapeutic strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI